Endurant Capital Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Endurant Capital Management’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-144,393	Closed	-$4.25M	–	67
2021 Q2	$4.25M	Buy	144,393 +2,070	+1%	+$59.2K	1.17%	34
2021 Q1	$3.92M	Buy	+142,323	New	+$4.25M	1.02%	36
2020 Q4	–	Sell	-111,467	Closed	-$2.67M	–	76
2020 Q3	$2.67M	Sell	111,467 -48,751	-30%	-$1.14M	0.79%	36
2020 Q2	$3.72M	Buy	+160,218	New	+$3.17M	0.2%	29

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Endurant Capital Management's CALT Position: Q3 2021 in Review

Endurant Capital Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2021, closing a stake of 144,393 shares — an estimated $4.25M sold.

Endurant Capital Management first reported a position in CALT in Q2 2020 and held it in 4 quarters. The position peaked at $4.25M in Q2 2021. 13 funds tracked by Wall St. Rank hold CALT as of Q3 2021.

Endurant Capital Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2021 after selling out during the quarter.
Endurant Capital Management sold 144,393 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2021, an estimated $4.25M.
Endurant Capital Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 4 quarters.
Endurant Capital Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $4.25M in Q2 2021.
13 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2021.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.